Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris.

Correction to: Journal of Nanobiotechnology (2022) 20:64 https://doi.org/10.1186/s12951-022-01272-5

Following publication of the original article [1], the authors identified an error in Fig. 1 and Fig. 4. The correct figures are given in this correction article.

The error was in the “R-groups” (R1 and R2) of the molecules IH18 and IH20 in Fig. 1b and in Additional file 1: Figure S1. R1 and R2 were accidently swapped. In Fig. 4d the error was in the depiction of the tumor/blood ratio. During transfer of the data to this bar graph the data got unintentionally transformed.

Fig. 1

Molecular toolbox of site-specific functionalizable anti-PD-L1 antibody formats and imaging peptides. A Application of the CRISPR/HDR strategy to anti-PD-L1 hybridoma MIH5 created a sortaggable Fab fragment and chimeric mouse IgG1 monoclonal antibody against PD-L1. B Molecular structure of imaging peptides IH20 and IH18

Fig. 4

Biodistribution results of anti-PD-L1 multimodal imaging tools. Biodistribution is shown at several time points after injection (p.i.) of 111In-labeled A mIgG1-IH18, B Fab-IH18 or C Fab-IH18-PEG. D Tumor uptake values (left graph) and tumor/blood ratios (right graph) of the three constructs are compared directly at each time point. Data are shown as mean ± SD, n = 5

Additional file 1. Supplementary figures and tables.